--- title: "Ardelyx (ARDX) news: offering" url: "https://aibio.space/companies/ardelyx/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "ARDX offering news: Ardelyx files automatic shelf with $100,000,000 ATM sales agreement supplement. Ardelyx, Inc. (NASDAQ: ARDX), United States." --- ARDX Ardelyx, Inc. NASDAQ · United States # Ardelyx (ARDX) news ARDX offering news Legal · 2026-08-06 ## [Ardelyx securities suit over Xphozah ends after appeal is withdrawn](https://aibio.space/news/ardelyx-securities-suit-xphozah-ends-after-appeal-withdrawn/) Yarborough v. Ardelyx named the company and executives Michael Raab, Susan Rodriguez, Laura Williams and Elizabeth Grammer. The First Circuit appeal was dismissed on March 26, 2026. ## Latest Ardelyx news 1. 2026-07-02 Debt Financing [Ardelyx draws $50.0 million Term F Loan under SLR Investment Corp. loan agreement, maturing 2030](https://aibio.space/news/ardelyx-draws-50-0-million-term-f-loan-under-slr-investment-corp-loan/) Ardelyx received the funds on June 29, 2026 under its 2022 loan and security agreement. The loan bears interest of 4.55% plus the greater of 1-month SOFR or 3.5%, with interest-only payments until July 1, 2030. 2. 2026-06-29 Debt Financing [Ardelyx draws $50.0 million term loan from SLR Investment Corp.](https://aibio.space/news/ardelyx-draws-50-0-million-term-loan-slr-investment-corp/) Ardelyx drew a $50.0 million Term F Loan from SLR Investment Corp. on June 29, 2026. The loan matures July 1, 2030 at 4.55% plus the greater of 1-month SOFR or 3.5%, and in a default the agent can reach the company's cash. 3. 2025-11-03 Financings [Ardelyx files automatic shelf with $100,000,000 ATM sales agreement supplement](https://aibio.space/news/ardelyx-files-automatic-shelf-100-000-000-atm-sales-agreement/) Jefferies LLC is the sales agent for up to $100,000,000 of common stock. A second Jefferies program, dated January 18, 2023, may still sell up to approximately $80.0 million. ## Ardelyx at a glance - **Ticker**: ARDX - **Listing**: NASDAQ - **Country**: United States - **Cash, Jun 30, 2026**: $281.8 million ### Related companies - [Veru](https://aibio.space/companies/veru/) NASDAQ: VERU - [Citius Oncology](https://aibio.space/companies/citius-oncology/) NASDAQ: CTOR - [HARD TO TREAT DISEASES INC](https://aibio.space/companies/hard-to-treat-diseases/) OTC: HTDS - [Viskase Holdings](https://aibio.space/companies/viskase/) OTC: VISK - [Acura Pharmaceuticals](https://aibio.space/companies/acura-pharmaceuticals/) OTC: ACUR - [Compass Therapeutics](https://aibio.space/companies/compass-therapeutics/) NASDAQ: CMPX - [Braveheart Bio](https://aibio.space/companies/braveheart-bio/) NASDAQ: BRVE - [Integrated BioPharma](https://aibio.space/companies/integrated-biopharma/) OTC: INBP ### Also on NASDAQ - [Solid Biosciences](https://aibio.space/companies/solid-biosciences/) SLDB - [Aytu BioPharma](https://aibio.space/companies/aytu-biopharma/) AYTU - [Anteris Technologies Global](https://aibio.space/companies/anteris-technologies-global/) AVR - [Aquestive Therapeutics](https://aibio.space/companies/aquestive-therapeutics/) AQST - [Taysha Gene Therapies](https://aibio.space/companies/taysha-gene-therapies/) TSHA - [Sanara MedTech](https://aibio.space/companies/sanara-medtech/) SMTI ## What Ardelyx does Ardelyx is a commercial-stage biopharmaceutical company focused on developing and commercializing innovative medicines for unmet medical needs. It markets two therapies from tenapanor, a minimally absorbed, first-in-class, oral small molecule sodium/hydrogen exchanger (NHE3) inhibitor that Ardelyx discovered and developed. IBSRELA is approved in the U.S. for adults with irritable bowel syndrome with constipation (IBS-C), and the company has initiated a Phase 3 trial of tenapanor in adults with chronic idiopathic constipation to expand that population. XPHOZAH is approved in the U.S. to reduce serum phosphorus in adults with chronic kidney disease on dialysis, as add-on therapy for patients with an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy. The company is also developing a next-generation NHE3 inhibitor with potential application across multiple therapeutic areas. The text says Ardelyx has incurred losses in each year since its inception in October 2007. | Product or program | What it is | Stage | |---|---|---| | IBSRELA | First-in-class NHE3 inhibitor for IBS-C in adults | approved in the U.S. | | XPHOZAH | Add-on therapy to reduce serum phosphorus in adults on dialysis | approved in the U.S. | Summarised from the company's [10-K filed Feb 19, 2026](https://www.sec.gov/Archives/edgar/data/1437402/000143740226000013/ardx-20251231.htm). ## Ardelyx annual financials | Line | FY2025 | FY2024 | |---|---|---| | Research and development | [$71.5 million](https://www.sec.gov/Archives/edgar/data/1437402/000143740226000013/) | [$52.3 million](https://www.sec.gov/Archives/edgar/data/1437402/000143740226000013/) | | Net income (loss) | [-$61.6 million](https://www.sec.gov/Archives/edgar/data/1437402/000143740226000013/) | [-$39.1 million](https://www.sec.gov/Archives/edgar/data/1437402/000143740226000013/) | | Cash from operations | [-$42.5 million](https://www.sec.gov/Archives/edgar/data/1437402/000143740226000013/) | [-$44.8 million](https://www.sec.gov/Archives/edgar/data/1437402/000143740226000013/) | | Cash and equivalents | [$68.0 million](https://www.sec.gov/Archives/edgar/data/1437402/000143740226000044/) | [$64.9 million](https://www.sec.gov/Archives/edgar/data/1437402/000143740226000013/) | | Short-term investments | [$196.7 million](https://www.sec.gov/Archives/edgar/data/1437402/000143740226000044/) | [$185.2 million](https://www.sec.gov/Archives/edgar/data/1437402/000143740226000013/) | Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $97.2 million, plus short-term investments of $184.6 million, $281.8 million in all. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about Ardelyx Has Ardelyx raised money recently? Our latest story on this, dated Nov 3, 2025: "Ardelyx files automatic shelf with $100,000,000 ATM sales agreement supplement". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/ardelyx-files-automatic-shelf-100-000-000-atm-sales-agreement/). What is the ticker symbol of Ardelyx? Ardelyx, Inc. trades under the ticker ARDX on NASDAQ. Where is Ardelyx listed? Ardelyx, Inc. is listed on NASDAQ. Our directory also records these other listings: GETTEX:41X; LS:A116X0; LSX:A116X0. What is the SEC CIK of Ardelyx? The SEC Central Index Key (CIK) for Ardelyx, Inc. is 1437402. Its filings are on SEC EDGAR. How many shares does Ardelyx have outstanding? 249,187,572 shares as of 2026-07-30, per the cover page of its 10-Q filed 2026-08-06. Which country or territory is Ardelyx listed under? Our directory records Ardelyx, Inc. under United States. What does Ardelyx do? Our directory classifies Ardelyx, Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline. What is the ISIN of Ardelyx? The ISIN recorded for Ardelyx, Inc. is US0396971071. Does aibio.space cover Ardelyx? aibio.space lists Ardelyx, Inc. among 2,820 public biotech companies and publishes its news here as stories appear. Where is Ardelyx incorporated? SEC records list its state or country of incorporation as DE. What does Ardelyx develop? Ardelyx is a commercial-stage biopharmaceutical company focused on developing and commercializing innovative medicines for unmet medical needs. It markets two therapies from tenapanor, a minimally absorbed, first-in-class, oral small molecule sodium/hydrogen exchanger (NHE3) inhibitor that Ardelyx discovered and developed. What is IBSRELA from Ardelyx? IBSRELA: First-in-class NHE3 inhibitor for IBS-C in adults Stage: approved in the U.S.. What is XPHOZAH from Ardelyx? XPHOZAH: Add-on therapy to reduce serum phosphorus in adults on dialysis Stage: approved in the U.S.. Is Ardelyx profitable? Ardelyx, Inc. reported a net loss of $61.6 million for the fiscal year ended Dec 31, 2025, and used $42.5 million of cash in operations, per its annual report to the SEC. How much does Ardelyx spend on research and development? $71.5 million in the fiscal year ended Dec 31, 2025, per its annual report. ## Investor discussion: Ardelyx Members talk about Ardelyx (ARDX). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at Ardelyx, newest first. Each line links the filing it comes from. 1. 2025-11-03 Financings Set up an at-the-market program to sell shares over time. SEC Form S-3ASR. [Source](https://www.sec.gov/Archives/edgar/data/1437402/000119312525262712/d34492ds3asr.htm) 2. 2025-02-20 Legal Disclosed a shareholder lawsuit, subpoena or other legal matter. SEC Form 10-K. [Source](https://www.sec.gov/Archives/edgar/data/1437402/000162828025006653/ardx-20241231.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:ARDX on TradingView](https://www.tradingview.com/symbols/NASDAQ-ARDX/). ## SEC filings and registration - **SEC name**: Ardelyx, Inc. - **CIK**: 1437402 - **Industry (SIC)**: Pharmaceutical Preparations (2834) - **US tickers**: ARDX (Nasdaq) - **State or country of incorporation**: DE - **Fiscal year ends**: December 31 - **Filer category**: Large accelerated filer - **Business address**: 34175 ARDENWOOD BLVD., FREMONT, CA, 94555 - **Phone**: 510-745-7047 - **Shares outstanding**: 249,187,572 as of 2026-07-30 (10-Q filed 2026-08-06) - **Former names**: NTERYX INC ### Recent filings (8-K and 6-K are the company's own announcements) - [8-K](https://www.sec.gov/Archives/edgar/data/1437402/000119312526354026/d921015d8k.htm) filed 2026-08-17 - [10-Q](https://www.sec.gov/Archives/edgar/data/1437402/000143740226000044/ardx-20260630.htm) filed 2026-08-06 - [8-K](https://www.sec.gov/Archives/edgar/data/1437402/000143740226000043/ardx-20260806.htm) filed 2026-08-06 - [8-K](https://www.sec.gov/Archives/edgar/data/1437402/000143740226000033/ardx-20260629.htm) filed 2026-07-02 - [8-K](https://www.sec.gov/Archives/edgar/data/1437402/000143740226000029/ardx-20260616.htm) filed 2026-06-17 - [10-Q](https://www.sec.gov/Archives/edgar/data/1437402/000143740226000022/ardx-20260331.htm) filed 2026-04-30 - [8-K](https://www.sec.gov/Archives/edgar/data/1437402/000143740226000021/ardx-20260430.htm) filed 2026-04-30 - [DEF 14A](https://www.sec.gov/Archives/edgar/data/1437402/000114036126017800/ny20065368x1_def14a.htm) filed 2026-04-29 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001437402), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details Ardelyx, Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker ARDX, recorded under United States. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: Ardelyx, Inc. - **Ticker**: ARDX - **Listing**: NASDAQ - **Country or territory**: United States - **Business scope**: Pharmaceuticals: Major - **ISIN**: US0396971071 - **Other listed symbols**: GETTEX:41X; LS:A116X0; LSX:A116X0 - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-ARDX/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/ardelyx/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Ardelyx (ARDX) news: offering", 2026-10-31, https://aibio.space/companies/ardelyx/